pretickt

Bio-Techne Corporation (TECH)

Healthcare · end-of-day data as of Oct 16, 2026

Bio-Techne Corporation
TECH · $11.38B
$72.57+1.5%last 60 sessions · close Oct 16, 2026
$43.17$72.6152 weeks
Hold · 13 analystsPT $67.46 -7.0%
  • P/E vs own-31.5%
  • P/E vs sector+122.2%
  • Target upside-7.0%
  • Off 52w high-0.1%
  • InsidersNone in 90d
  • FCF yield+2.3%
  • Earnings in19d
  • Trendsideways
  • Sector▲ +16.0%
  • RSI58
  • MA20×50—
  • Volume0.9x
  • Support-1.1%
  • Resistance+6.2%

The average 12-month analyst price target for TECH is $67.46, 7.0% below the last close of $72.57 on Oct 16, 2026; targets range from $51.52 to $75.43. Rating consensus: Hold.

Snapshot

  • P/E62.6x
  • P/E vs sector+122.2%
  • P/E vs own-31.5%
  • Target upside-7.0%
  • ConsensusHold
  • Market cap$11.38B
  • FCF yield+2.3%
  • InsidersNone in 90d
  • Earnings in19d
  • News0.00

Why it moved

Bio-Techne Corporation (TECH) rose 0.1% on Oct 16, 2026.

The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.

Market (SPY)-1.1%
Healthcare sector+0.4%
TECH specific+0.8%

0 stories on the day (30-day average 0.4).

Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.

Price and events

⇔⇕$45.08$53.62$62.16$70.70Oct 25Jan 26Apr 26Jul 26Oct 26EDAEDEDAAAAEADE

Last close $72.57 · +18.5% over 1y · E earnings · D dividend · S split · A analyst rating change

Technicals

  • Trendsideways
  • Sector▲ +16.0%
  • MAs20▲ 50▲ 100▲ 200▲
  • Above MAs4 of 4 above
  • MA20×50—
  • RSI58
  • Support-1.1%
  • Resistance+6.2%
  • Off 52w high-0.1%
  • Off ATH-44.9%
  • 52w range$72.57
  • Bollingerupper half
  • MACD-0.02
  • ATR+0.2%
  • Volume0.9x

Analyst price targets

Low$51.52
Average$67.46
Median$72.75
High$75.43
Upside-7.0%

11 firms with a target in the last 12 months · last close $72.57 · as of Oct 16, 2026

⇔⇕$41.56$50.43$59.30$68.17$77.05Oct 25Feb 26Jun 26Oct 26Feb 27Jun 27-7%-6%-24%-1%+0%
— actual price● bullish target● bearish targethover a dot to see the analysts behind it · wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets

Strong buy 0 · Buy 1 · Hold 12 · Sell 0 · Strong sell 0

Revenue and free cash flow

Q4 FY2026: Revenue +1.3% year over year, free cash flow 27.1% of revenue, operating margin 23.1%.

RevenueFree cash flow
Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026
Q4 FY2026Jun 30, 2026$321M0.36$86.94M65.8%23.1%17.0%
Q3 FY2026Mar 31, 2026$311M0.32$77.58M66.9%24.2%16.4%
Q2 FY2026Dec 31, 2025$296M0.24$76.49M64.6%18.4%12.8%
Q1 FY2026Sep 30, 2025$287M0.24$22.22M65.6%16.6%13.3%
Q4 FY2025Jun 30, 2025$317M-0.11$93.31M62.7%-7.5%-5.6%
Q3 FY2025Mar 31, 2025$316M0.14$31M67.9%12.2%7.1%
Q2 FY2025Dec 31, 2024$297M0.22$77.53M65.3%16.0%11.7%
Q1 FY2025Sep 30, 2024$289M0.21$54.72M63.2%13.8%11.6%

Peers

20D
1VRTXVertex Pharmaceuticals Incorporated$499.74-1.8%-10.4%+14.0%29.1$127B
2MRNAModerna, Inc.$218.01-7.8%-7.8%-25.0%—$87.04B
3REGNRegeneron Pharmaceuticals, Inc.$790.74-0.7%-7.2%+8.7%19.6$81.41B
4ALNYAlnylam Pharmaceuticals, Inc.$231.83-0.9%-52.8%+61.5%39.2$31.02B
5INCYIncyte Corporation$113.07-0.2%-13.0%+13.6%14.4$22.92B
6TECHBio-Techne Corporation$72.57+0.1%-0.1%-7.0%62.6$11.38B
7COOThe Cooper Companies, Inc.$57.94+0.9%-31.3%+0.9%19.8$11.02B
8UHSUniversal Health Services, Inc.$185.10-1.2%-23.9%+11.1%7.6$10.91B

Data as of Oct 16, 2026 close.

Latest news

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.